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Background
CRS-207 is live-attenuated, double-deleted Listeria
monocytogenes (LADD) engineered to express the
tumor-associated antigen mesothelin which is highly
expressed in malignant pleural mesothelioma (MPM).
CRS-207 stimulates potent innate and adaptive immu-
nity and in combination with chemotherapy may act
synergistically to alter the tumor environment to be
more susceptible to immune-mediated killing. Prelimin-
ary data of 32 patients who received CRS-207 in combi-
nation with pemetrexed/cisplatin showed 60% partial
responses and 94% disease control[1]. Low-dose cyclo-
phosphamide (Cy) in combination with LADD improved
immune and anti-tumor responses and overall survival
in preclinical studies.
Methods
Up to 60 subjects are planned to be enrolled in 2 mutually
exclusive, sequential cohorts at 5 clinical trial sites.
Patients must be chemotherapy-naïve, have unresectable
MPM, good performance status (ECOG 0 or 1) and ade-
quate organ function. Eligible patients in Cohort 1 receive
2 prime vaccinations with CRS-207 (1 × 109 CFU; 250 mL
IV over 2 hours) 2 weeks apart, followed by up to 6 cycles
of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2)
3 weeks apart and 2 CRS-207 boost vaccinations 3 weeks
apart. Subjects are followed every 8 weeks until disease
progression. Clinically stable patients continue CRS-207
maintenance vaccinations every 8 weeks. Patients in
Cohort 2 receive low-dose Cy (200 mg/m2) 1 day prior to
each CRS-207 vaccination. Objectives of the study are
safety, immunogenicity, objective tumor responses and
tumor marker kinetics.
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